BioWorld

March 5, 2004

View Archived Issues

Inhibitex Files For IPO; Veronate Slated To Start Phase III In 2004

Inhibitex Inc. joined the ranks of private biotech companies looking to take advantage of a more receptive market with an initial public offering filing aimed at raising $86.25 million. (BioWorld Today) Read More

CTI Cleared For Pixantrone Trial; Strong Pipeline Backs NHL Drug

Read More

Legislation Could Help Patent Office Keep Fees, Add To Staff

Read More

After Pulling IPO, Acorda Raises $11.5M Through Private Round

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More